Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma

NCT03120676 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT03120676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03120676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
April 14, 2017
Completion date
November 12, 2018
Enrollment
3 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma